Skip to main content

Table 2 Best Overall Response

From: A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Group Cohort 1 (N = 30) Cohort 2 (N = 15) Assessment 1 (N = 39) Assessment 2 (N = 15)
Complete Response 3 (10%) 1 (7%) 4 (10%) 4 (27%)
95% CI (%) (2, 27) (0.2, 32) (3, 24) (8, 55)
Response (CR/PR) 8 (27%) 4 (27%) 11 (28%) 9 (60%)
95% CI (%) (12, 46) (8, 55) (15, 45) (33, 84)
Disease Control (CR/PR/SD) 23 (77%) 11 (73%) 30 (77%) 15 (100%)
95% CI (%) (58, 90) (45, 92) (61, 89) (78, 100)